France's 3-Year Medical Cannabis Experiment: 3% Had Serious Side Effects
Among 3,164 patients in France's medical cannabis program, 3% experienced serious adverse reactions — mainly neurological, GI, and psychiatric — with 6 acute coronary events and 8 suicidal thoughts but no psychosis and only 1 case of misuse.
Quick Facts
What This Study Found
37.5% of patients reported at least one ADR; 3% had serious ADRs; most common: neurological (37.2%), GI (16.9%), psychiatric (15.2%); 6 acute coronary syndromes; 8 suicidal thoughts (half without prior psychiatric history); 1 misuse case; 0 psychosis.
Key Numbers
3,164 patients; 37.5% ≥1 ADR; 3% serious; 6 acute coronary syndromes; 8 suicidal thoughts (4 without prior psychiatric history); 1 suicide attempt; 7 withdrawal syndromes; 1 misuse; 0 psychosis cases.
How They Did This
Observational safety analysis of the French national medical cannabis experimentation registry (RECANN) plus pharmacovigilance/addictovigilance databases from March 2021 to March 2024, covering 3,164 patients.
Why This Research Matters
France's cautious, government-monitored approach to medical cannabis provides the most rigorous safety data from a national program — the 3% serious event rate and absence of psychosis are reassuring.
The Bigger Picture
The absence of psychosis cases in 3,000+ patients under medical supervision contrasts sharply with recreational use concerns — suggesting that controlled medical use has a meaningfully different risk profile.
What This Study Doesn't Tell Us
Observational without comparator group; under-reporting likely in registry systems; 3-year timeframe may miss long-term effects; French patient selection criteria may differ from other programs.
Questions This Raises
- ?Would the safety profile differ with longer follow-up?
- ?Should the coronary syndrome cases prompt cardiac screening for medical cannabis patients?
Trust & Context
- Key Stat:
- Evidence Grade:
- Large national registry with systematic pharmacovigilance monitoring, but observational without control group and subject to reporting bias.
- Study Age:
- Published in 2026 covering 2021-2024, providing 3 years of safety data from a carefully controlled national program.
- Original Title:
- Medical Cannabis Use in France: An Observational Safety Study Based on the RECANN Registry and the Pharmacovigilance/Addictovigilance System From 2021 to 2024.
- Published In:
- Fundamental & clinical pharmacology, 40(2), e70074 (2026)
- Authors:
- Chevallier, Cécile, Batisse, Anne, Monzon, Emilie, Richard, Nathalie, Authier, Nicolas, Chenaf, Chouki, Gaboriau, Louise, Ferey, Véronique, Chretien, Basile, Fedrizzi, Sophie, Auffret, Marine
- Database ID:
- RTHC-08166
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
How safe is medical cannabis in France's program?
About 3% of patients had serious adverse reactions over 3 years. No psychosis was documented, and only 1 case of misuse was identified among 3,164 patients under medical supervision.
What are the most common side effects of medical cannabis?
Neurological effects (37%) were most common, followed by gastrointestinal (17%) and psychiatric (15%). Most were not serious, but 6 cases of acute coronary syndrome and 8 cases of suicidal thoughts were reported.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-08166APA
Chevallier, Cécile; Batisse, Anne; Monzon, Emilie; Richard, Nathalie; Authier, Nicolas; Chenaf, Chouki; Gaboriau, Louise; Ferey, Véronique; Chretien, Basile; Fedrizzi, Sophie; Auffret, Marine. (2026). Medical Cannabis Use in France: An Observational Safety Study Based on the RECANN Registry and the Pharmacovigilance/Addictovigilance System From 2021 to 2024.. Fundamental & clinical pharmacology, 40(2), e70074. https://doi.org/10.1111/fcp.70074
MLA
Chevallier, Cécile, et al. "Medical Cannabis Use in France: An Observational Safety Study Based on the RECANN Registry and the Pharmacovigilance/Addictovigilance System From 2021 to 2024.." Fundamental & clinical pharmacology, 2026. https://doi.org/10.1111/fcp.70074
RethinkTHC
RethinkTHC Research Database. "Medical Cannabis Use in France: An Observational Safety Stud..." RTHC-08166. Retrieved from https://rethinkthc.com/research/chevallier-2026-medical-cannabis-use-in
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.